KZIA - Kazia Therapeutics Ltd ADR News

Kazia Therapeutics Files Provisional Patent Application Supporting Therapeutic Strategy Designed To

Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology company developing thera

globenewswire.com

Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Precl

Clinically relevant perioperative studies demonstrate elimination of residual disease and prevention

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Ther

Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tol

Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scie

SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology

Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development P

SYDNEY, Australia, April 13, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), a clini

12 Health Care Stocks Moving In Wednesday's Intraday Session

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrade

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metas

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of P

SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical u

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translatio

SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chie

12 Health Care Stocks Moving In Monday's Intraday Session

Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

defenseworld.net

Short Interest in Novogen Limited (NASDAQ:KZIA) Decreases By 35.4%

Novogen Limited (NASDAQ: KZIA - Get Free Report) was the target of a large drop in short interest du

defenseworld.net

Novogen (NASDAQ:KZIA) & Opthea (NASDAQ:OPT) Head to Head Analysis

Novogen (NASDAQ: KZIA - Get Free Report) and Opthea (NASDAQ: OPT - Get Free Report) are both small-c

Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-

12 Health Care Stocks Moving In Tuesday's Intraday Session

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Abil

First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions

12 Health Care Stocks Moving In Tuesday's After-Market Session

What's Going On With Cancer Firm Kazia Therapeutics

Kazia Therapeutics Limited (NASDAQ: KZIA) announced a private placement of approximately $50 million

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

SYDNEY , Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused

12 Health Care Stocks Moving In Wednesday's Intraday Session

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q

SYDNEY , Nov. 18, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focuse

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potenti

SYDNEY , Oct. 27, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") today a

Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Prote

SYDNEY , Oct. 7, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused

Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNB

SYDNEY , Oct. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused

Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy S

SYDNEY , Oct. 1, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage bi

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in S

SYDNEY , Sept. 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focus

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Prema

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Sess

Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Sess

US Stocks Edge Higher; Inflation Slows To 3% In June

12 Health Care Stocks Moving In Monday's After-Market Session

Stocks That Hit 52-Week Lows On Thursday

On Thursday, 241 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

On Monday, 413 companies reached new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 838 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Thursday

On Thursday, 1076 companies hit new 52-week lows.

On Wednesday, 340 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

On Friday, 109 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

On Monday, 92 companies set new 52-week lows.

During Wednesday's session, 326 stocks hit new 52-week lows.

On Wednesday, 329 companies hit new 52-week lows.

On Wednesday, 807 companies reached new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's session saw 729 companies set new 52-week lows.